A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients

Transplantation

Volumn 62, Issue 8, 1996, Pages 1063-1068

  Winkler, Michael ^a   Haller, Garry ^b   Oldhafer, Karl ^a   Bechstein, Wolf Otto ^b   Kattner, Astrid ^a   Maibucher, Axel ^c   Farber, Lothar ^c   Ringe, Burghardt ^d   Christians, Uwe ^a   Neuhaus, Peter ^b   Pichlmayr, Rudolf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Klinische Forschung   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG FORMULATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; EMULSIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MICROCHEMISTRY; MIDDLE AGED;

EID: 10344244468     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610270-00006     Document Type: Article

References (25)

1. Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy, 1993; 13: 613.
2. Kovarik JM, Vernillet L, Mueller EA, Freiburghaus R, Niederberger W, Kutz K. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit 1993; 16: 519.
3. Levy G, Rochon J, Freeman D, et al. Cyclosporine Neoral in liver transplant recipients. Transplant Proc 1994; 26: 2949.
4. Levy G, Grant D. Potential for CsA-Neoral in organ transplantation. Transplant Proc 1995; 26: 2932.
5. Atkison PR, Grant DR, Williams SE, Howard J, Wall WJ, Stiller CR. Sandimmune Neoral in paediatric liver transplant recipients with malabsorption of CyA. Transplant Proc 1994; 25: 2953.
6. Färber F, Maibücher A, Gessler F, Gutzler F, Wiesinger FO, Winkler M. Favourable clinical results of Sandimmun Neoral in malabsorbing liver and heart transplant recipents. Transplant Proc 1994; 25: 2988.
7. Trull AK, Tan KKC, Uttridge J, Tredger JM. Cyclosporine absorption from microemulsion formulation in a liver transplant recipient. Lancet 1993; 341: 433.
8. Winkler M, Ringe B, Schneider K, Maibücher A, et al. Enhanced bioavailability of cyclosporine A using a new oral formulation (Sandimmun Optoral) in a liver grafted patient with severe cholestasis. Transplant Int 1994; 7: 147.
9. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplant Proc 1990; 22: 1110.
10. Meta MU, Venkataramanan R, Burchardt GJ, Starzl TE. Effect of bile on cyclosporine absorption in liver transplant patients. Br J Clin Pharmacol 1988; 25: 579.
11. Naoumov NV, Tredger JM, Steward CM, et al. Cyclosporine A pharmakokinetics in liver transplant recipients in relation to biliary T tube clamping and liver dysfunction. Gut 1989; 30: 391.
12. European FK 506 multicenter trial group: randomized trial comparing tacrolimus and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423.
13. Altraif I, Levy G, Grant D. Pharmacokinetic studies of Sandimmune Neoral vs. Sandimmune in liver transplant recipients. Hepatology 1993; 18: 747.
14. Jamieson NV, Rasmussen A. Chronic and acute rejection in liver transplant patients. In: Salman J, ed. Long term cyclosporin therapy and risk of chronic rejection: a discussion. (Round tables series; No 34). London: Royal Society of Medicine 1994: 38.
15. Jamieson N. De novo use of Neoral in liver transplant recipients. In: ed. Neoral: the new microemulsion formulation of cyclosporine. Cedars Knoll, NJ: World Medical 1995: 34.
16. Levy G. Neoral in liver transplantation: clinical and experimental perspectives in Sandimmune therapy. Cedars Knoll, NJ: World Medical Press 1995; 5: 1.
17. Levy G. The potential for Sandimmune Neoral in liver transplantation. In: Neoral: the new microemulsion formulation of cyclosporine. Cedars Knoll NJ, World Medical Press, 1995: 40.
18. Trull AK, Tan KKC, Tan L, Alexander GJM, Jamieson NV. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external bile diversion. Transplant Proc 1994; 26: 2977.
19. Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213.
20. Trull AK, Tan KKC, Tan L, Alexander GJM, Jamieson NV. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995; 39: 627.
21. Tredger JM, McCarthy M, Williams R, et al. Is cyclosporin Neoral a viable alternative to intravenous Sandimmune early after liver transplantation? The pharmacokinetic evidence. Transplant Int (in press).
22. Mayer AD. Gupta S, Jamieson NV, et al. Neoral (cyclosporin A) replaces the need for intravenous Sandimmun in triple therapy induction after liver transplantation: the clinical experience. Transplant Int (in press).
23. Mueller EA, Kallay Z, Kovarik JM, et al. Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. Transplantation 1995; 60: 515.
24. Winkler M, Ringe B, Oldhafer K, et al. Influence of bile on cyclosporine absorption from microemulsion formulation in primary liver transplant recipients. Transplant Int 1995; 8: 324.
25. Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period - predictive of chronic rejection in liver transplantation? Transplantation 1995; 59: 1119.